
Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection
BURLINGTON, N.C., April 23, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.
'Labcorp is dedicated to providing oncologists with a comprehensive portfolio of innovative solutions that enable precise, timely and personalized treatment decisions,' said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. 'With the expansion of our portfolio to include Labcorp Plasma Detect for clinical use and the availability of PGDx elio plasma focus Dx to support patient treatment selection, we're advancing care across the oncology spectrum, solidifying our commitment to transforming cancer diagnostics and improving patient outcomes.'
Labcorp Plasma Detect: Advanced Risk Assessment for Colon Cancer PatientsStage III colon cancer has a nearly 30% recurrence rate within five years. Labcorp Plasma Detect is a blood-based test using whole-genome sequencing (WGS) to detect circulating tumor DNA (ctDNA), indicating the presence of molecular residual disease (MRD).i Patients who are MRD-positive after cancer treatment have a higher risk of recurrence and a poorer prognosis. Labcorp's test detects cancer recurrence risk that conventional methods might miss, helping to identify patients who could benefit from additional treatment or therapy.
Key Features of Labcorp Plasma Detect:
The test is Labcorp's first tumor-informed MRD solution for clinical use to support recurrence risk stratification. Labcorp Plasma Detect launched in 2024 for biopharma use to support exploratory and investigational studies.
The test combines a WGS approach, without the need for a bespoke panel, with proprietary bioinformatics to deliver ctDNA detection down to a limit of detection (LOD95) of 0.005%.
Results are available approximately 14 days after Labcorp receives the initial sample, and seven days for subsequent monitoring time points for each patient.
Labcorp Plasma Detect is currently being evaluated in more than 10 clinical studies in the U.S. and internationally to assess MRD across various cancer types.
Labcorp Plasma Detect will be offered initially through an Early Experience Program, with the intent to expand availability more broadly.
PGDx elio plasma focus Dx Now Available for Use to Aid in Treatment SelectionPGDx elio plasma focus Dx is the first and only kitted pan-solid tumor liquid biopsy test to receive De Novo authorization from the FDA. This assay provides oncologists with a validated tool to assess various solid tumors for targeted treatment selection – all from a simple blood draw.
Key Features of PGDx elio plasma focus Dx:
The kitted model allows clinical laboratories and hospitals to retain control over patient specimens and data for research, care management and other clinical purposes.
As an FDA-authorized assay, PGDx elio plasma focus Dx requires only on-site verification – as opposed to a full validation – enabling more rapid implementation.
Once implemented, this rapid, scalable liquid biopsy genomic test provides actionable findings within a 4-to-5-day turnaround time, from isolated nucleic acid to variant report.
As part of the PGDx elio platform, the kitted model is compatible with FDA-cleared PGDx elio™ tissue complete, enabling seamless, in-house tissue-to-liquid reflexing and efficient comprehensive genomic profiling workflows.
Labcorp at the American Association for Cancer Research (AACR) 2025 Annual MeetingLabcorp will present key studies at the AACR 2025 Annual Meeting, including the clinical use of Labcorp Plasma Detect and performance of PGDx elio plasma focus Dx.
To learn more, or to connect with Labcorp at AACR in Chicago, visit https://oncology.labcorp.com/american-association-cancer-research-annual-meeting-2025
For more information about Labcorp's Oncology solutions, contact us at https://oncology.labcorp.com/contact-us
About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
i The term MRD is often used interchangeably between molecular residual disease and minimal residual disease. Labcorp Plasma Detect detects molecular residual disease, which is defined as the subclinical presence of a cancer-associated biomarker indicating a high risk of recurrence, which cannot be detected by standard imaging techniques. MRD terminology is in accordance with the BLOODPAC Consortium.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
2 hours ago
- Malaysian Reserve
InventHelp Inventor Develops Newly Designed Oscillating Tool (HOF-684)
PITTSBURGH, July 24, 2025 /PRNewswire/ — 'I wanted to create a new oscillating cutting tool to increase accuracy and control when executing plunge cuts and cutting in tight spaces,' said an inventor, from Friendswood, Texas, 'so I invented The Ultimate Multi-Tool. My design helps prevent mistakes and poor cuts.' The patent-pending invention provides an improved design for an oscillating tool. The tool features an increased rate of base material removal resulting in faster cutting. It also allows for greater control of the cutting edge resulting in more accurate cuts. Additionally, it reduces vibration and noise levels, it reduces user fatigue, and it saves time and effort. The invention features a durable design that is easy to use so it is ideal for trade workers, laborers, do-it-yourselfers, etc. The original design was submitted to the Houston sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-HOF-684, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at


Malaysian Reserve
3 hours ago
- Malaysian Reserve
New ASTHO Legal Map Illuminates State and Territorial Suicide Prevention Infrastructure
ARLINGTON, Va., July 24, 2025 /PRNewswire/ — The Association of State and Territorial Health Officials (ASTHO), in partnership with Temple University and with support from the Centers for Disease Control and Prevention (CDC), today announced the release of a new interactive resource, Legal Mapping of State and Territorial Infrastructure to Prevent Suicides. The tool visualizes state and territorial laws, as of January 1, 2025, related to suicide prevention commissions, offices, and fatality review processes, providing invaluable insights for strengthening prevention efforts nationwide. Suicide remains a significant public health crisis, ranking as the second-leading cause of death for individuals ages 10-34 in 2023, with over 49,000 suicides occurring across all age groups that year. Certain populations experience disproportionately higher rates of suicide, including those in rural areas, older adults, American Indian or Alaska Native individuals, people with disabilities, and veterans. 'Understanding the variability of legal frameworks for suicide prevention infrastructure across jurisdictions can help leaders identify ways they might strengthen their own work,' says Joseph Kanter, MD, MPH, ASTHO CEO. 'These new legal maps help jurisdictions examine the national landscape of policies, enable health agencies to pinpoint gaps, replicate best practices, and strategically implement evidence-based interventions tailored to their communities' unique needs. Strong, legally supported infrastructure is paramount to sustaining prevention efforts, especially amid evolving funding landscapes.' The interactive resource allows users to explore various aspects of state and territorial suicide prevention infrastructure, including: The establishment of suicide prevention offices or coordinators The existence of population-focused suicide prevention groups or taskforces The establishment and scope of committees or bodies that review suicide fatalities, including data collection on suicide attempts and information sharing requirements Key findings regarding the legal landscape of state-level infrastructure as of January 1, 2025: Twelve jurisdictions had laws establishing a suicide prevention office or coordinator, with eight of these offices located within health departments Twelve jurisdictions have laws establishing suicide prevention task forces, commissions, or other advisory bodies Thirty jurisdictions had a law establishing a committee, body, or other review process for some portion of suicide fatalities On July 30, ASTHO is hosting a webinar focused on the new resource. Register here: State and Territorial Infrastructure for Suicide Prevention: Exploring New Legal Maps. ASTHO is the national nonprofit organization representing the public health agencies of the United States, the U.S. territories and freely associated states, and Washington, D.C., as well as the more than 100,000 public health professionals these agencies employ. ASTHO members, the chief health officials of these jurisdictions, are dedicated to formulating and influencing sound public health policy and to ensuring excellence in public health practice.


Malaysian Reserve
3 hours ago
- Malaysian Reserve
AtWork Group Reports a Strong First Half of 2025
Staffing Franchise Expands with New Locations and Earns Top Industry Honors KNOXVILLE, Tenn., July 24, 2025 /PRNewswire/ — AtWork®, an award-winning leader in the staffing industry, is proud to announce significant growth and recognition in the first half of 2025. Amid a cautiously optimistic outlook for the staffing industry, AtWork continues to outpace expectations with new office openings, strong franchise development, and multiple national awards. 'Despite the headwinds facing the staffing industry, the first two quarters of 2025 have proven to be a period of strength for AtWork,' said Jason Leverant, president and COO of AtWork. 'Our ability to adapt to evolving workforce needs while maintaining our commitment to client and candidate satisfaction continues to set us apart.' New Locations AtWork continues to grow its national footprint in 2025. Arkansas became the latest state to join AtWork's growing list of markets, further expanding the brand's national presence. AtWork opened eight new offices across the country so far in 2025: Virginia: Richmond South Georgia: Cartersville Georgia: West Gwinnett South Carolina: Greenville Washington: Seattle Southwest Arkansas: Bentonville Texas: Austin Northeast Indiana: Indianapolis NW Awards & Recognition AtWork earned several prestigious industry honors in 2025, including: Forbes' List of America's Best Recruiting and Temporary Staffing Firms (2025) – Recognized among the top 200 U.S. firms in the temporary staffing category. Staffing Industry Analysts' (SIA) 2025 Largest Staffing Firms in the US-Recognizing AtWork's impact and scale in the staffing industry. ClearlyRated Best of Staffing® Client and Talent Awards (2025) – Awarded to fewer than 1% of staffing firms in the U.S. and Canada. Franchise Business Review's 2025 Top Franchises Satisfaction Award – Based on independent surveys of franchisee satisfaction. FranServe Fran-tastic brand-Honored for exceptional commitment in helping individuals realize their dream of owning a business by providing strong franchise opportunities. A stand-out franchisee, Josephine Suryono, who owns and operates AtWork locations in Sacramento and Roseville, California, has received several accolades for her success this year. Josephine was named the International Franchise Association's Franchisee of the Year as well as a 2025 Franchise Rockstar by Franchise Business Review in the Women's category. Her Roseville office led the AtWork system in revenue and gross profit in 2024 and continues to set a high standard in 2025. Additional Achievements In the first half of 2025, AtWork's leadership remained actively involved in national workforce conversations: COO Jason Leverant published a practical employment AI Guide designed to help job seekers navigate the evolving job market with new technology. Leverant's expertise has been featured in Newsweek, Yahoo! News, The Washington Examiner and other major outlets, covering topics such as Gen Z's fear of layoffs, the transition of federal workers into private sector roles, and the shifting landscape for white-collar employment. With over 30 years in business, AtWork remains committed to supporting entrepreneurs, connecting businesses with high-quality talent, and delivering exceptional staffing solutions nationwide. To learn more about AtWork's franchise opportunities, visit About AtWork Headquartered in Knoxville, Tennessee, AtWork is an award-winning staffing franchise with nearly 100 locations. For more than 30 years, leading companies from across the nation have trusted AtWork to recruit the best talent. Recognized by Staffing Industry Analysts as one of the Largest and Best Staffing Firms to work for in the U.S. and as an Entrepreneur Verified Franchise, AtWork can staff an entire production facility or provide temporary support that keeps businesses thriving. AtWork's dedication and unparalleled service earned them a spot on Forbes America's Best Recruiting and Temporary Staffing Firms and ClearlyRated's Best of Staffing® award for client and talent satisfaction. Additionally, the franchise's growth and support for its franchisees have secured them a place on Franchise Business Review's (FBR) Top 200 Franchise ranking for seven years in a row and is in the FBR Hall of Fame for 10+ years of stellar performance. AtWork is also ranked in Entrepreneur's Franchise 500, Franchise Times Top 400, and Entrepreneur's Top Franchises for Diversity, Equity, and Inclusion. To learn more about AtWork's services, visit Media Contact: Lu Dumas919.459.8168ldumas@